Stephen Ross

Biography

Mr. Ross is a 25-year veteran on the global sales, marketing, and commercial strategy side of the healthcare industry. Before joining Galera Therapeutics, he served for eight years as Chief Commercial Officer of Ikaria, Inc., a leading critical care drug manufacturer. Ikaria was acquired by Mallinckrodt for $2.3 billion in 2015. Mr. Ross also held many commercial roles over a 15-year period with GlaxoSmithKline, including Sr. Vice President of the UK subsidiary’s $2 billion specialty products division, General Manager of GSK’s Irish subsidiary, and marketing leadership of GSK’s billion dollar US oncology portfolio. Over the course of his career, Mr. Ross has developed a deep understanding of hospital specialty products, particularly cancer therapeutics and supportive care products. He holds an undergraduate degree in economics from Brigham Young University, and an MBA in marketing and finance from the Wharton School of the University of Pennsylvania.         Mr. Ross is a 25-year veteran on the global sales, marketing, and commercial strategy side of the healthcare industry. Before joining Galera Therapeutics, he served for eight years as Chief Commercial Officer of Ikaria, Inc., a leading critical care drug manufacturer. Ikaria was acquired by Mallinckrodt for $2.3 billion in 2015. Mr. Ross also held many commercial roles over a 15-year period with GlaxoSmithKline, including Sr. Vice President of the UK subsidiary’s $2 billion specialty products division, General Manager of GSK’s Irish subsidiary, and marketing leadership of GSK’s billion dollar US oncology portfolio. Over the course of his career, Mr. Ross has developed a deep understanding of hospital specialty products, particularly cancer therapeutics and supportive care products. He holds an undergraduate degree in economics from Brigham Young University, and an MBA in marketing and finance from the Wharton School of the University of Pennsylvania.        

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters